Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

GLUTRONICS(TM) Appoints Brad Boruk as Co-Chief Executive Officer

By: ACCESS Newswire

May 18, 2026 at 09:55 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

GLUTRONICS™ is proud to announce: Appoints Brad Boruk as Co-Chief Executive Officer

DALLAS, TX / ACCESS Newswire / May 18, 2026 / GLUTRONICS™, a medical technology startup focused on non-invasive glucose monitoring, today announced the appointment of Brad Boruk as Co-Chief Executive Officer. Boruk will serve alongside Co-CEO Dr. Hoon Kim, who continues to lead the company's technology development and research initiatives. The appointment reflects the company's intent to expand its commercial and strategic capabilities as it advances its technology toward potential future commercialization.

Company Overview

GLUTRONICS™ is developing non-invasive glucose monitoring technology designed to provide metabolic health data without traditional finger-prick testing. The company's technology is currently in development and has not been cleared or approved by the FDA or any other regulatory authority. GLUTRONICS™ believes its approach has the potential to contribute to the evolution of how glucose levels are monitored, though significant development, testing, and regulatory milestones remain before any commercial product could be available.

Role and Responsibilities

As Co-CEO, Boruk will focus on business development, strategic partnerships, and commercialization planning, including:

Evaluating potential licensing and distribution relationships
Exploring international manufacturing partnerships
Supporting intellectual property strategy
Coordinating the company's FDA regulatory pathway
Assessing opportunities for integration with wearable health technology platforms

Dr. Kim will continue to oversee the company's research and development efforts, technical team, and product engineering.

"We see significant long-term potential in non-invasive glucose monitoring technology," said Boruk. "My focus will be on building the strategic relationships and commercial infrastructure needed to support GLUTRONICS™ as it works toward bringing its technology to market."

Market Context

The global market for glucose monitoring and metabolic health technology continues to grow, driven in part by increasing demand for less invasive monitoring alternatives, remote patient monitoring solutions, and wearable health technologies. GLUTRONICS™ believes these trends may create future opportunities for its technology, subject to successful development, regulatory clearance, and commercial viability.

Current Status

GLUTRONICS™ is currently in the development stage and is evaluating potential strategic relationships with manufacturing, distribution, and technology partners as part of its long-term planning. The company has not commenced commercial operations and its technology remains subject to further development and regulatory review.

Media Inquiries

Brad Boruk Co-Chief Executive Officer, GLUTRONICS™
Email: b.boruk@glutronics.com Phone: (469) 964-6699

About GLUTRONICS™

GLUTRONICS™ is a development-stage medical technology company working on non-invasive glucose monitoring solutions and wearable healthcare technologies. The company's products are not currently available for commercial sale.

Regulatory Disclaimer

The glucose monitoring technology described in this press release has not been cleared or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. The product is currently in development and is not available for commercial sale. No claims are made herein regarding the diagnostic, therapeutic, or medical efficacy of the technology.

This press release contains forward-looking statements, including statements regarding the company's technology, business strategy, anticipated partnerships, regulatory plans, and commercialization timeline. These statements are based on current expectations and assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. GLUTRONICS undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

GLUTRONICS™ is a trademark of GLUTRONICS. All other trademarks referenced herein are the property of their respective owners.

SOURCE: GluTronics LLC

View the original press release on ACCESS Newswire

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	263.97	-2.35 (-0.88%)
AAPL	310.25	+1.43 (0.46%)
AMD	496.74	+29.23 (6.25%)
BAC	52.15	+0.35 (0.67%)
GOOG	382.57	+3.19 (0.84%)
META	610.64	+0.38 (0.06%)
MSFT	415.48	-3.09 (-0.74%)
NVDA	213.37	-1.96 (-0.91%)
ORCL	191.72	-0.37 (-0.19%)
TSLA	432.31	+6.30 (1.48%)